Kelly N H Nudelman1, Brenna C McDonald1, Yang Wang1, Dori J Smith1, John D West1, Darren P O'Neill1, Noah R Zanville1, Victoria L Champion1, Bryan P Schneider1, Andrew J Saykin2. 1. Kelly N.H. Nudelman, Brenna C. McDonald, Yang Wang, Dori J. Smith, John D. West, Darren P. O'Neill, Victoria L. Champion, Bryan P. Schneider, and Andrew J. Saykin, Indiana University School of Medicine; Noah R. Zanville and Victoria L. Champion, Indiana University School of Nursing, Indianapolis, IN; and Yang Wang, Medical College of Wisconsin, Milwaukee, WI. 2. Kelly N.H. Nudelman, Brenna C. McDonald, Yang Wang, Dori J. Smith, John D. West, Darren P. O'Neill, Victoria L. Champion, Bryan P. Schneider, and Andrew J. Saykin, Indiana University School of Medicine; Noah R. Zanville and Victoria L. Champion, Indiana University School of Nursing, Indianapolis, IN; and Yang Wang, Medical College of Wisconsin, Milwaukee, WI. asaykin@iupui.edu.
Abstract
PURPOSE: To investigate the longitudinal relationship between chemotherapy-induced peripheral neuropathy (CIPN) symptoms (sx) and brain perfusion changes in patients with breast cancer. Interaction of CIPN-sx perfusion effects with known chemotherapy-associated gray matter density decrease was also assessed to elucidate the relationship between CIPN and previously reported cancer treatment-related brain structural changes. METHODS: Patients with breast cancer treated with (n = 24) or without (n = 23) chemotherapy underwent clinical examination and brain magnetic resonance imaging at the following three time points: before treatment (baseline), 1 month after treatment completion, and 1 year after the 1-month assessment. CIPN-sx were evaluated with the self-reported Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity four-item sensory-specific scale. Perfusion and gray matter density were assessed using voxel-based pulsed arterial spin labeling and morphometric analyses and tested for association with CIPN-sx in the patients who received chemotherapy. RESULTS: Patients who received chemotherapy reported significantly increased CIPN-sx from baseline to 1 month, with partial recovery by 1 year (P < .001). CIPN-sx increase from baseline to 1 month was significantly greater for patients who received chemotherapy compared with those who did not (P = .001). At 1 month, neuroimaging showed that for the group that received chemotherapy, CIPN-sx were positively associated with cerebral perfusion in the right superior frontal gyrus and cingulate gyrus, regions associated with pain processing (P < .001). Longitudinal magnetic resonance imaging analysis in the group receiving chemotherapy indicated that CIPN-sx and associated perfusion changes from baseline to 1 month were also positively correlated with gray matter density change (P < .005). CONCLUSION: Peripheral neuropathy symptoms after systemic chemotherapy for breast cancer are associated with changes in cerebral perfusion and gray matter. The specific mechanisms warrant further investigation given the potential diagnostic and therapeutic implications.
PURPOSE: To investigate the longitudinal relationship between chemotherapy-induced peripheral neuropathy (CIPN) symptoms (sx) and brain perfusion changes in patients with breast cancer. Interaction of CIPN-sx perfusion effects with known chemotherapy-associated gray matter density decrease was also assessed to elucidate the relationship between CIPN and previously reported cancer treatment-related brain structural changes. METHODS:Patients with breast cancer treated with (n = 24) or without (n = 23) chemotherapy underwent clinical examination and brain magnetic resonance imaging at the following three time points: before treatment (baseline), 1 month after treatment completion, and 1 year after the 1-month assessment. CIPN-sx were evaluated with the self-reported Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity four-item sensory-specific scale. Perfusion and gray matter density were assessed using voxel-based pulsed arterial spin labeling and morphometric analyses and tested for association with CIPN-sx in the patients who received chemotherapy. RESULTS:Patients who received chemotherapy reported significantly increased CIPN-sx from baseline to 1 month, with partial recovery by 1 year (P < .001). CIPN-sx increase from baseline to 1 month was significantly greater for patients who received chemotherapy compared with those who did not (P = .001). At 1 month, neuroimaging showed that for the group that received chemotherapy, CIPN-sx were positively associated with cerebral perfusion in the right superior frontal gyrus and cingulate gyrus, regions associated with pain processing (P < .001). Longitudinal magnetic resonance imaging analysis in the group receiving chemotherapy indicated that CIPN-sx and associated perfusion changes from baseline to 1 month were also positively correlated with gray matter density change (P < .005). CONCLUSION:Peripheral neuropathy symptoms after systemic chemotherapy for breast cancer are associated with changes in cerebral perfusion and gray matter. The specific mechanisms warrant further investigation given the potential diagnostic and therapeutic implications.
Authors: Kathleen A Griffith; Ingemar S J Merkies; Elizabeth E Hill; David R Cornblath Journal: J Peripher Nerv Syst Date: 2010-12 Impact factor: 3.494
Authors: Yang Wang; Andrew J Saykin; Josef Pfeuffer; Chen Lin; Kristine M Mosier; Li Shen; Sungeun Kim; Gary D Hutchins Journal: Neuroimage Date: 2010-08-25 Impact factor: 6.556
Authors: Alexander Tzabazis; Carina Mari Aparici; Michael C Rowbotham; M Bret Schneider; Amit Etkin; David C Yeomans Journal: Mol Pain Date: 2013-07-02 Impact factor: 3.395
Authors: Elaine G Boland; Dinesh Selvarajah; Mike Hunter; Yousef Ezaydi; Solomon Tesfaye; Sam H Ahmedzai; John A Snowden; Iain D Wilkinson Journal: PLoS One Date: 2014-05-12 Impact factor: 3.240
Authors: Jaymin Upadhyay; Christian Geber; Richard Hargreaves; Frank Birklein; David Borsook Journal: Neurosci Biobehav Rev Date: 2017-08-12 Impact factor: 8.989
Authors: D D Correa; J C Root; M Kryza-Lacombe; M Mehta; S Karimi; M L Hensley; N Relkin Journal: Brain Imaging Behav Date: 2017-12 Impact factor: 3.978
Authors: Scott M Monfort; Xueliang Pan; Robyn Patrick; Bhuvaneswari Ramaswamy; Robert Wesolowski; Michelle J Naughton; Charles L Loprinzi; Ajit M W Chaudhari; Maryam B Lustberg Journal: Breast Cancer Res Treat Date: 2017-04-03 Impact factor: 4.872
Authors: John R Keltner; Alan Tong; Eelke Visser; Mark Jenkinson; Colm G Connolly; Alyssa Dasca; Aleks Sheringov; Zachary Calvo; Earl Umbao; Rohit Mande; Mary Beth Bilder; Gagandeep Sahota; Donald R Franklin; Stephanie Corkran; Igor Grant; Sarah Archibald; Florin Vaida; Gregory G Brown; J Hampton Atkinson; Alan N Simmons; Ronald J Ellis Journal: J Neurovirol Date: 2020-06-10 Impact factor: 3.739
Authors: Noah R Zanville; Kelly N H Nudelman; Dori J Smith; Diane Von Ah; Brenna C McDonald; Victoria L Champion; Andrew J Saykin Journal: Support Care Cancer Date: 2016-07-28 Impact factor: 3.603
Authors: Judith A Paice; Matt Mulvey; Michael Bennett; Patrick M Dougherty; John T Farrar; Patrick W Mantyh; Christine Miaskowski; Brian Schmidt; Thomas J Smith Journal: J Pain Date: 2016-11-21 Impact factor: 5.820